Treating active rheumatoid arthritis with Janus kinase inhibitors

The Lancet

Volumn 390, Issue 10093, 2017, Pages 431-432

  Scott, David L ^a   Stevenson, Matt D ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BARICITINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; JANUS KINASE INHIBITOR; METHOTREXATE; SALAZOSULFAPYRIDINE; TOFACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; NOTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; JANUS KINASE INHIBITORS; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 85020810167     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31659-8     Document Type: Note

References (13)

1. Fleischmann, R, Mysler, E, Hall, S, et al., on behalf of the ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet, 2017 published online June 16 http://dx.doi.org/10.1016/S0140-6736(17)31618-5.
2. JR O'Dell, Mikuls, TR, Taylor, TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369 (2013), 307–318.
3. Scott, DL, Ibrahim, F, Farewell, V, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ, 350, 2015, h1046.
4. Taylor, PC, Keystone, EC, van der Heijde, D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376 (2017), 652–662.
5. Kremer, J, Li, ZG, Hall, S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159 (2013), 253–261.
6. Singh, JA, Hossain, A, Tanjong, Ghogomu E, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev, 5, 2016, CD012183.
7. Nikiphorou, E, Buch, MH, Hyrich, KL, Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol, 2017, 10.1038/nrrheum.2017.81 published online June 1.
8. Tarp, S, Furst, DE, Boers, M, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology 56 (2017), 417–425.
9. Singh, JA, Saag, KG, Bridges, SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68 (2016), 1–25.
10. Hazlewood, GS, Barnabe, C, Tomlinson, G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ, 353, 2016, i1777.
11. Smolen, JS, Landewé, R, Bijlsma, J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76 (2017), 960–977.
12. Sauer, BC, Teng, CC, Tang, D, et al. Persistence with conventional triple therapy versus a tumor necrosis factor inhibitor and methotrexate in US veterans with rheumatoid arthritis. Arthritis Care Res 69 (2017), 313–322.
13. Stevenson, MD, Wailoo, AJ, Tosh, JC, et al. The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. J Rheumatol, 2017, 10.3899/jrheum.160941 published online Feb 17.